Premium
Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials
Author(s) -
Rodeghiero Francesco,
Stasi Roberto,
Giagounidis Aristoteles,
Viallard JeanFrançois,
Godeau Bertrand,
Pabinger Ingrid,
Cines Douglas,
Liebman Howard,
Wang Xuena,
Woodard Paul
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12181
Subject(s) - romiplostim , medicine , tolerability , adverse effect , eltrombopag , clinical endpoint , discontinuation , clinical trial , placebo , surgery , thrombopoietin , immune thrombocytopenia , platelet , pathology , genetics , haematopoiesis , biology , alternative medicine , stem cell
Background and objectives Thrombopoietin receptor agonists ( TPO ra) are the only treatments for immune thrombocytopenia ( ITP ) for which evidence of efficacy and safety from randomized, placebo‐controlled trials is available. We sought to determine the long‐term tolerability of the TPO ra romiplostim, with a particular focus on thrombosis, bleeding, bone marrow ( BM ) reticulin, neoplasms/haematological malignancies and fatal events. Methods Data from 13 romiplostim clinical trials in which 653 patients with ITP received romiplostim for up to 5 yr (921.5 patient‐years) were pooled; subject incidence rates and exposure‐adjusted event rates (per 100 patient‐years) were calculated. Results The rate of thrombotic events (6% of patients, 7.5 events per 100 patient‐years) did not appear to increase over time; 9 events were associated with platelet counts >400 × 10 9 /L and 10 with romiplostim doses exceeding current recommendations. Serious and grade ≥3 bleeding each occurred in approximately 8% of patients (~11 events per 100 patient‐years). Adverse events of BM reticulin were recorded for 12 patients (1.8%, 1.3 events per 100 patient‐years, confirmed by bone biopsy in ten patients) and BM collagen for one patient (0.2%, 0.1 event per 100 patient‐years, confirmed by trichrome staining). Neoplasms and haematological malignancies occurred in 2.1% and 0.8% of patients, respectively (2.2 and 0.7 events per 100 patient‐years). Fatal events occurred in 3.7% of patients (2.6 events per 100 patient‐years, four events treatment‐related). Conclusions Romiplostim is the TPO ra for which the longest duration of safety data is available. Our data demonstrate that long‐term romiplostim treatment is well tolerated, with no new safety signals, even in patients treated for up to 5 yr.